Eli Lilly and Company has recently introduced Zepbound (tirzepatide) in 2.5mg and 5mg single-dose vials. These vials are now available to self-pay patients with on-label prescriptions. The high demand for Zepbound, an obesity treatment, is addressed by this action, which considerably increases access to the medication. The new vials are priced at a 50% or greater discount in comparison to other incretin (GLP-1) medications for obesity, thereby offering a more affordable option for patients.
LillyDirect, a self-pay pharmacy platform that guarantees patients receive authentic Lilly medications, offers the single-dose vials. The objective of this new distribution channel is to safeguard consumers from hazardous or counterfeit products. Patients who are ineligible for the Zepbound savings card or do not have insurance coverage can now obtain the medication at a reduced cost.
The 2.5 mg vials are priced at $399 for a four-week supply, while the 5 mg vials are priced at $549, providing a more cost-effective obesity treatment option. James Zervos, COO of the Obesity Action Coalition, emphasized the importance of this move, stating, “People living with obesity have long been denied access to the essential treatment and care needed to manage this serious chronic disease." Lilly continues to be a leader in the development of remedies for chronic diseases, providing care to more than 51 million patients worldwide.
